TRVN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:26):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
Today's Volume	11 188.00
Average Volume	211 404
Market Cap	5.99M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.470 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0.00600 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.78
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

Volume Correlation

Long: -0.11 (neutral)

Short: -0.06 (neutral)

Signal:(42.169) Neutral

Trevena Inc Correlation

10 Most Positive Correlations
AVO	0.962
SWVL	0.94
RPID	0.938
QLGN	0.938
ARQQ	0.936
XFOR	0.934
LYRA	0.932
ASPS	0.932
ALZN	0.93
GOSS	0.929

10 Most Negative Correlations
STAY	-0.95
ACAB	-0.943
GLLI	-0.942
FNVT	-0.939
HZNP	-0.937
CIIG	-0.936
AVAC	-0.933
NWFL	-0.931
TIPT	-0.929
LRFC	-0.929

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevena Inc Correlation - Currency/Commodity

-0.19
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.25
( neutral )

Trevena Inc Financials

Annual	2022
Revenue:	$-418 000
Gross Profit:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2022
Revenue:	$-418 000
Gross Profit:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
Revenue:	$567.00
Gross Profit:	$-387.00 (-68.25 %)
EPS:	$-0.0101

FY	2020
Revenue:	$3.07M
Gross Profit:	$2.89M (94.07 %)
EPS:	$-5.75

Financial Reports:

No articles found.

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.